2015 Jury Chairman
M. John Chapman B.Sc. (Hons), Ph.D., D.Sc., FESC, Research Professor at the Medical Faculty of the Pierre and Marie Curie University, (UPMC), in Paris, Director Emeritus of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpêtrière University Hospital in Paris, France, and Past-President of the European Atherosclerosis Society (EAS). As President of EAS from 2009 to 2013, he actively supported the development of new Joint Guidelines for the Management of Dyslipidemia with the European Society of Cardiology. Together with Prof. Henry Ginsberg, he spearheads the EAS Consensus Panel initiatives and Consensus Papers; this initiative has focused to date on Lipoprotein Lp(a), on atherogenic high triglyceride/low HDL dyslipidemia as a major cardiovascular risk factor, on the underdiagnosis and undertreatment of familial hypercholesterolemia, on the genetics of hypertriglyceridemic states, and on plant sterols and stanols in the management of dyslipidemia and prevention of cardiovascular disease; these Consensus Paper publications have achieved worldwide visibility. A current EAS Consensus Panel is focused on intolerance to statin therapy.
Professor Chapman undertook his undergraduate studies at Aberdeen University, Scotland and at the Middlesex Hospital Medical School, University of London. He subsequently trained in Cardiovascular Lipidology at the Cardiovascular Research Institute of the University of California Medical Center, San Francisco, CA, USA and at the Gladstone Foundation for Cardiovascular Disease in the same city.
John Chapman is Associate European Editor of Pharmacology and Therapeutics and a member of the Editorial Board of Arteriosclerosis, Thrombosis and Vascular Biology, Atherosclerosis, Vascular Pharmacology, Future Lipidology and Current Medical Research and Opinion. He has authored numerous publications and book chapters and has presented plenary conferences worldwide. In 2012, an authoritative treatise on High-Density Lipoproteins, entitled HDL: Structure, Metabolism, Function and Therapeutics, and co-authored by Dr. Anatol Kontush and Prof. Chapman, was published by Wiley.
Professor Chapman serves on several international Advisory Boards and on Steering Committees of clinical intervention trials aimed at development of novel therapeutic approaches to attenuate dyslipidemia and atherosclerotic vascular disease.
In 2009, he received a Distinguished Career Award from the International Atherosclerosis Society for his contributions to the field of HDL biology. In 2011, Professor Chapman chaired the Gordon Research Conference on Atherosclerosis in Newport, RI, USA, and in 2010 and 2011, was awarded Prizes for Scientific Excellence by INSERM. Professor Chapman is Laureate of the European Lipid Science Award for 2014. Present research interests are focused on (i) the intravascular metabolism and pharmacological modulation of atherogenic apoB-containing lipoproteins, and (ii) the structure, molecular composition and functionality of HDL particle subpopulations in the atherogenic dyslipidemias, and (iii) the development of new anti-atherosclerotic therapeutics for the prevention of cardiovascular disease.